The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...

The participants were randomly assigned on a 1:1 basis to either receive self-administered 2 mg extended-release subcutaneous injection of exenatide or placebo once a week for 96 weeks.

Your browser does not support the audio element. India’s premier motor show, the Auto Expo 2025, is underway, and some big names have shown important models ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Common side effects include nausea, diarrhea, constipation, vomiting, indigestion, and injection site reactions ... acting version of the GLP-1 agonist exenatide, used to help control blood ...